{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:58:41Z","timestamp":1775278721280,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s12272-022-01423-0","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T19:02:37Z","timestamp":1671822157000},"page":"111-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects"],"prefix":"10.1007","volume":"46","author":[{"given":"Chang\u2011Keun","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Young","family":"Byeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pureum","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye-Jung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunvin","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chou Yen","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choon-Gon","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4162-1981","authenticated-orcid":false,"given":"Seok-Yong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Jeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"issue":"2","key":"1423_CR1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5414\/cpp45110","volume":"45","author":"JW Bae","year":"2007","unstructured":"Bae JW, Kim MJ, Park YS, Myung CS, Jang CG, Lee SY (2007) Considerable interindividual variation in the pharmacokinetics of tolperisone HCl. Int J Clin Pharmacol Ther 45(2):110\u2013113. https:\/\/doi.org\/10.5414\/cpp45110","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"11","key":"1423_CR2","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s12272-020-01293-4","volume":"43","author":"JW Bae","year":"2020","unstructured":"Bae JW, Oh KY, Yoon SJ, Shin HB, Jung EH, Cho CK, Lim CW, Kang P, Choi CI, Jang CG, Lee SY, Lee YJ (2020) Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide. Arch Pharm Res 43(11):1207\u20131213. https:\/\/doi.org\/10.1007\/s12272-020-01293-4","journal-title":"Arch Pharm Res"},{"key":"1423_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1090-3801(02)00145-3","volume":"7","author":"P Bajaj","year":"2003","unstructured":"Bajaj P, Arendt-Nielsen L, Madeleine P, Svensson P (2003) Prophylactic tolperisone for post-exercise muscle soreness causes reduced isometric force: a double-blind radomized crossover control study. Eur J Pain 7:407\u2013418","journal-title":"Eur J Pain"},{"issue":"8","key":"1423_CR4","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.clinthera.2013.07.147","volume":"35","author":"JY Byeon","year":"2013","unstructured":"Byeon JY, Lee JY, Jeon JS, Lee JE, Kim SH, Bae JW, Jang CG, Lee SY (2013) Pharmacokinetics of tolperisone in relation to CYP2C19 genotypes. Clinical Therapeutics 35(8):e54. https:\/\/doi.org\/10.1016\/j.clinthera.2013.07.147","journal-title":"Clinical Therapeutics"},{"issue":"11","key":"1423_CR5","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s12272-021-01357-z","volume":"44","author":"CK Cho","year":"2021","unstructured":"Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2021a) Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele. Arch Pharm Res 44(11):1037\u20131049. https:\/\/doi.org\/10.1007\/s12272-021-01357-z","journal-title":"Arch Pharm Res"},{"issue":"12","key":"1423_CR6","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1007\/s12272-021-01361-3","volume":"44","author":"CK Cho","year":"2021","unstructured":"Cho CK, Park HJ, Kang P, Moon S, Lee YJ, Bae JW, Jang CG, Lee SY (2021b) Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes. Arch Pharm Res 44(12):1076\u20131090. https:\/\/doi.org\/10.1007\/s12272-021-01361-3","journal-title":"Arch Pharm Res"},{"issue":"5","key":"1423_CR7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s12272-022-01388-0","volume":"45","author":"CK Cho","year":"2022","unstructured":"Cho CK, Kang P, Park HJ, Ko E, Mu CY, Lee YJ, Choi CI, Kim HS, Jang CG, Bae JW, Lee SY (2022) Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism. Arch Pharm Res 45(5):352\u2013366. https:\/\/doi.org\/10.1007\/s12272-022-01388-0","journal-title":"Arch Pharm Res"},{"key":"1423_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-022-01422-1","volume-title":"Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisone","author":"CK Cho","year":"2023","unstructured":"Cho CK, Byeon JY, Kang P, Park JI, Jang CG, Lee SY, Choi CI, Nae JW, Lee J (2023) Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisone. Arch Pharm Res 46(1) in press. https:\/\/doi.org\/10.1007\/s12272-022-01422-1"},{"key":"1423_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jchromb.2012.10.027","volume":"911","author":"CI Choi","year":"2012","unstructured":"Choi CI, Park JI, Lee HI, Lee YJ, Jang CG, Bae JW, Lee SY (2012) Determination of tolperisone in human plasma by liquid chromatography\/tandem mass spectrometry for clinical application. J Chromatogr B Analyt Technol Biomed Life Sci 911:59\u201363. https:\/\/doi.org\/10.1016\/j.jchromb.2012.10.027","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"1","key":"1423_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/JCP.0b013e3182a608a2","volume":"34","author":"CI Choi","year":"2014","unstructured":"Choi CI, Bae JW, Lee YJ, Lee HI, Jang CG, Lee SY (2014) Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics. J Clin Psychopharmacol 34(1):139\u2013142. https:\/\/doi.org\/10.1097\/JCP.0b013e3182a608a2","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"1423_CR11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1124\/dmd.31.5.631","volume":"31","author":"B Dalmadi","year":"2003","unstructured":"Dalmadi B, Leibinger J, Szeber\u00e9nyi S, Borb\u00e1s T, Farkas S, Szombathelyi Z, Tihanyi K (2003) Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos 31(5):631\u2013636. https:\/\/doi.org\/10.1124\/dmd.31.5.631","journal-title":"Drug Metab Dispos"},{"key":"1423_CR12","doi-asserted-by":"publisher","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","volume":"269","author":"SM de Morais","year":"1994","unstructured":"de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994a) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419\u201315422","journal-title":"J Biol Chem"},{"key":"1423_CR13","first-page":"594","volume":"46","author":"SM de Morais","year":"1994","unstructured":"de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994b) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594\u2013598","journal-title":"Mol Pharmacol"},{"key":"1423_CR14","first-page":"125","volume":"4","author":"H Fukuda","year":"1970","unstructured":"Fukuda H, Watanabe K, Kudo Y, Oshima T, Ito T (1970) Pharmacological studies on a centrally acting muscle relaxant, 2,4\u2019-dimethyl-3-piperidinopropiophenone, Mydocalm. Pharmacometrics 4:125\u2013130","journal-title":"Pharmacometrics"},{"issue":"9","key":"1423_CR15","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s12272-020-01250-1","volume":"43","author":"EH Jung","year":"2020","unstructured":"Jung EH, Lee CM, Byeon JY, Shin HB, Oh KY, Cho CK, Lim CW, Jang CG, Lee SY, Lee YJ (2020a) Relationship between plasma exposure of zolpidem and CYP2D6 genotype in healthy Korean subjects. Arch Pharm Res 43(9):976\u2013981. https:\/\/doi.org\/10.1007\/s12272-020-01250-1","journal-title":"Arch Pharm Res"},{"issue":"12","key":"1423_CR16","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1007\/s12272-020-01300-8","volume":"43","author":"EH Jung","year":"2020","unstructured":"Jung EH, Lee YJ, Kim DH, Kang P, Lim CW, Cho CK, Jang CG, Lee SY, Bae JW (2020b) Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes. Arch Pharm Res 43(12):1356\u20131363. https:\/\/doi.org\/10.1007\/s12272-020-01300-8","journal-title":"Arch Pharm Res"},{"issue":"12","key":"1423_CR17","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s12272-021-01363-1","volume":"44","author":"EH Jung","year":"2021","unstructured":"Jung EH, Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Choi CI, Jang CG, Lee SY (2021) Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients. Arch Pharm Res 44(12):1109\u20131119. https:\/\/doi.org\/10.1007\/s12272-021-01363-1","journal-title":"Arch Pharm Res"},{"issue":"4","key":"1423_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jphs.2019.03.001","volume":"139","author":"C Kamiya","year":"2019","unstructured":"Kamiya C, Inui N, Hakamata A, Miyakawa S, Tanaka S, Uchida S, Namiki N, Odagiri K, Watanabe H (2019) Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype. J Pharmacol Sci 139(4):361\u2013366. https:\/\/doi.org\/10.1016\/j.jphs.2019.03.001","journal-title":"J Pharmacol Sci"},{"issue":"8","key":"1423_CR19","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/jcph.323","volume":"54","author":"M Kara\u017aniewicz-\u0141ada","year":"2014","unstructured":"Kara\u017aniewicz-\u0141ada M, Danielak D, Rubi\u015b B, Burchardt P, Oszkinis G, G\u0142\u00f3wka F (2014) The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. J Clin Pharmacol 54(8):874\u2013880. https:\/\/doi.org\/10.1002\/jcph.323","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"1423_CR20","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s12272-021-01346-2","volume":"44","author":"YH Kim","year":"2021","unstructured":"Kim YH, Kang P, Cho CK, Jung EH, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2021) Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism. Arch Pharm Res 44(7):713\u2013724. https:\/\/doi.org\/10.1007\/s12272-021-01346-2","journal-title":"Arch Pharm Res"},{"issue":"2","key":"1423_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12272-021-01366-y","volume":"45","author":"NT Kim","year":"2022","unstructured":"Kim NT, Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2022) Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects. Arch Pharm Res 45(2):114\u2013121. https:\/\/doi.org\/10.1007\/s12272-021-01366-y","journal-title":"Arch Pharm Res"},{"issue":"3","key":"1423_CR22","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1124\/jpet.105.089805","volume":"315","author":"P Kocsis","year":"2005","unstructured":"Kocsis P, Farkas S, Fodor L, Bielik N, Th\u00e1n M, Kolok S, Gere A, Csejtei M, Tarnawa I (2005) Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther 315(3):1237\u20131246. https:\/\/doi.org\/10.1124\/jpet.105.089805","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"1423_CR23","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00228-018-2522-5","volume":"74","author":"HI Lee","year":"2018","unstructured":"Lee HI, Byeon JY, Kim YH, Lee CM, Choi CI, Jang CG, Bae JW, Lee YJ, Lee SY (2018) Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites. Eur J Clin Pharmacol 74(11):1417\u20131426. https:\/\/doi.org\/10.1007\/s00228-018-2522-5","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1423_CR24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s12272-022-01394-2","volume":"45","author":"CM Lee","year":"2022","unstructured":"Lee CM, Kang P, Cho CK, Park HJ, Lee YJ, Bae JW, Choi CI, Kim HS, Jang CG, Lee SY (2022) Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes. Arch Pharm Res 45(6):433\u2013445. https:\/\/doi.org\/10.1007\/s12272-022-01394-2","journal-title":"Arch Pharm Res"},{"issue":"5","key":"1423_CR25","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3109\/15563650.2015.1022896","volume":"53","author":"V Martos","year":"2015","unstructured":"Martos V, Hofer KE, Rauber-L\u00fcthy C, Schenk-Jaeger KM, Kupferschmidt H, Ceschi A (2015) Acute toxicity profile of tolperisone in overdose: observational poison centre-based study. Clin Toxicol (phila) 53(5):470\u2013476. https:\/\/doi.org\/10.3109\/15563650.2015.1022896","journal-title":"Clin Toxicol (phila)"},{"issue":"7","key":"1423_CR26","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/0731-7085(87)80082-1","volume":"5","author":"P Miskolczi","year":"1987","unstructured":"Miskolczi P, Vereczkey L, Frenkl R (1987) Gas-liquid chromatographic method for the determination of tolperisone in human plasma: pharmacokinetic and comparative bioavailability studies. J Pharm Biomed Anal 5(7):695\u2013700. https:\/\/doi.org\/10.1016\/0731-7085(87)80082-1","journal-title":"J Pharm Biomed Anal"},{"issue":"12","key":"1423_CR27","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1002\/cpdd.966","volume":"10","author":"JY Na","year":"2021","unstructured":"Na JY, Jeon I, Yoon J, Choi Y, Yoon SH, Yu KS, Chung JY (2021) Influence of CYP2C19 polymorphisms on the pharmacokinetics of omeprazole in elderly subjects. Clin Pharmacol Drug Dev 10(12):1469\u20131477. https:\/\/doi.org\/10.1002\/cpdd.966","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"1423_CR28","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00228-015-1856-5","volume":"71","author":"M Pawlowska","year":"2015","unstructured":"Pawlowska M, Bogiel M, Duda J, Sieradzki E (2015) Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers. Eur J Clin Pharmacol 71(6):699\u2013705. https:\/\/doi.org\/10.1007\/s00228-015-1856-5","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"1423_CR29","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s12272-020-01294-3","volume":"43","author":"HB Shin","year":"2020","unstructured":"Shin HB, Jung EH, Kang P, Lim CW, Oh KY, Cho CK, Lee YJ, Choi CI, Jang CG, Lee SY, Bae JW (2020) ABCB1 c.2677G>T\/c.3435C>T diplotype increases the early-phase oral absorption of losartan. Arch Pharm Res 43(11):1187\u20131196. https:\/\/doi.org\/10.1007\/s12272-020-01294-3","journal-title":"Arch Pharm Res"},{"issue":"1","key":"1423_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","volume":"79","author":"SC Sim","year":"2006","unstructured":"Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79(1):103\u2013113. https:\/\/doi.org\/10.1016\/j.clpt.2005.10.002","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1423_CR31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/ejhpharm-2020-002367","volume":"29","author":"C Song","year":"2022","unstructured":"Song C, Li X, Mao P, Song W, Liu L, Zhang Y (2022) Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy. Eur J Hosp Pharm 29(4):198\u2013201. https:\/\/doi.org\/10.1136\/ejhpharm-2020-002367","journal-title":"Eur J Hosp Pharm"},{"key":"1423_CR32","first-page":"127","volume":"58","author":"A Vora","year":"2010","unstructured":"Vora A (2010) Tolperisone. J Assoc Physicians India 58:127\u2013128","journal-title":"J Assoc Physicians India"},{"issue":"8","key":"1423_CR33","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s12272-022-01403-4","volume":"45","author":"SS Whang","year":"2022","unstructured":"Whang SS, Cho CK, Jung EH, Kang P, Park HJ, Lee YJ, Choi CI, Bae JW, Kim HS, Jang CG, Lee SY (2022) Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes. Arch Pharm Res 45(8):584\u2013595. https:\/\/doi.org\/10.1007\/s12272-022-01403-4","journal-title":"Arch Pharm Res"},{"key":"1423_CR34","doi-asserted-by":"publisher","first-page":"104606","DOI":"10.1016\/j.phrs.2019.104606","volume":"152","author":"HJ Zhang","year":"2020","unstructured":"Zhang HJ, Zhang XH, Liu J, Sun LN, Shen YW, Zhou C, Zhang HW, Xie LJ, Chen J, Liu Y, Wang YQ (2020) Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors. Pharmacol Res 152:104606. https:\/\/doi.org\/10.1016\/j.phrs.2019.104606","journal-title":"Pharmacol Res"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-022-01423-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-022-01423-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-022-01423-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T23:09:03Z","timestamp":1677107343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-022-01423-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1423"],"URL":"https:\/\/doi.org\/10.1007\/s12272-022-01423-0","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]},"assertion":[{"value":"15 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}